Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod

Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod

Bibliographic Details
Main Authors:	Kensuke Senzaki, Hirofumi Ochi, Masayuki Ochi, Yoko Okada, Shiroh Miura, Yasumasa Ohyagi
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	eNeurologicalSci
Subjects:	Multiple sclerosis Fingolimod Siponimod Disease reactivation Sphingosine-1-phosphate receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2405650221000381

Similar Items

Does Siponimod Exert Direct Effects in the Central Nervous System?
by: Markus Kipp
Published: (2020-07-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
by: Gajofatto A
Published: (2017-11-01)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
by: Newshan Behrangi, et al.
Published: (2019-01-01)

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01)

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod
by: Ryoko Fukai, et al.
Published: (2019-07-01)

Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency
by: Gulin Sunter, et al.
Published: (2018-04-01)

New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01)

Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
by: Brandon Brown, et al.
Published: (2019-11-01)

Effect of fingolimod on platelet count among multiple sclerosis patients
by: Mehrdad Farrokhi, et al.
Published: (2015-01-01)

Neuronal Metabolism and Neuroprotection: Neuroprotective Effect of Fingolimod on Menadione-Induced Mitochondrial Damage
by: Antonio Gil, et al.
Published: (2021-12-01)

Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study
by: Carlo Gesualdo, et al.
Published: (2021-09-01)

Importance of apolipoprotein A-I in multiple sclerosis
by: Lidia A Gardner, et al.
Published: (2015-11-01)

Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
by: Tristan Rupp, et al.
Published: (2021-01-01)

Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases
by: Sara Grassi, et al.
Published: (2019-07-01)

CRITICAL APPRAISAL OF EFFECTIVENESS OF ORAL FINGOLIMOD ON RELAPSING MULTIPLE SCLEROSIS
by: Rizaldy Taslim Pinzon, et al.
Published: (2017-11-01)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
by: Abdoreza Naser Moghadasi, et al.
Published: (2020-07-01)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021-04-01)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
by: Gajofatto A, et al.
Published: (2015-12-01)

Sphingosine-1-Phosphate in Pancreatic Ductal Adenocarcinoma
by: Cardenas, Alex
Published: (2013)

Role of sphingosine 1-phosphate (S1P) and effects of fingolimod, an S1P receptor 1 functional antagonist in lymphocyte circulation and autoimmune diseases
by: Kenji Chiba, et al.
Published: (2014-11-01)

Morpholino Analogues of Fingolimod as Novel and Selective S1P<sub>1</sub> Ligands with In Vivo Efficacy in a Mouse Model of Experimental Antigen-Induced Encephalomyelitis
by: Bisera Stepanovska, et al.
Published: (2020-09-01)

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
by: Masoud Etemadifar, et al.
Published: (2017-02-01)

Safety of generic fingolimod
by: O. M. Koval, et al.
Published: (2018-03-01)

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
by: Correale J, et al.
Published: (2016-06-01)

Comparing the Quality of Life in Patients With Multiple Sclerosis Consuming Fingolimod and Cinnovex
by: Alia Saberi, et al.
Published: (2019-11-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Weight Loss and Fingolimod
by: Nefati Kıylıoğlu
Published: (2017-12-01)

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
by: Morteza Abdar, et al.
Published: (2017-03-01)

Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod
by: Pushpinder Kaur, et al.
Published: (2020-01-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
by: Miraç Ayşen Ünsal
Published: (2019-03-01)

Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review
by: M. Martinot, et al.
Published: (2020-03-01)

Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS)
by: N Razazian, et al.
Published: (2020-04-01)

Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
by: Chih-Chao Yang, et al.
Published: (2021-01-01)

Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
by: Canan Duman İlki, et al.
Published: (2020-03-01)

HOW DOES FINGOLIMOD (GILENYA®) FIT IN THE TREATMENT ALGORITHM FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS?
by: Franz eFazekas, et al.
Published: (2013-05-01)

Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study
by: Zimmer A, et al.
Published: (2017-10-01)

Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study
by: Zimmer, Andrea, et al.
Published: (2017)

Sphingosine-1-Phosphate Modulates Dendritic Cell Function: Focus on Non-Migratory Effects in Vitro and in Vivo
by: Olga Arlt, et al.
Published: (2014-06-01)

A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
by: Mehrdokht Mazdeh, et al.
Published: (2019-04-01)